[1]吴佳欣 谢旭东.Ang-(1-12)/Chymase轴：新型胞内分泌机制为治疗开辟新方向[J].心血管病学进展,2019,(8):1090-1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.005]
　WU Jiaxin,XIE Xudong.Ang-(1-12)/Chymase Axis:Novel Intracrine Mechanism for Open ing a New Era of Therapy[J].Advances in Cardiovascular Diseases,2019,(8):1090-1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.005]
点击复制

Ang-(1-12)/Chymase轴：新型胞内分泌机制为治疗开辟新方向()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1090-1094
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Ang-(1-12)/Chymase Axis:Novel Intracrine Mechanism for Open ing a New Era of Therapy
作者:
吴佳欣 谢旭东
(浙江大学附属第一医院心血管内科,浙江 杭州 310003 )
Author(s):
WU Jiaxin; XIE Xudong
(Department of Cardiology,The First Affiliated Hospital of Zhejiang University,Hangzhou 310003,Zhejiang,China)
关键词:
血管紧张素-(1-12); 糜蛋白酶; 肾素-血管紧张素系统; 血管紧张素肽; 胞内分泌
Keywords:
Angiotensin-(1-12);  Chymase;  Renin-angiotensin system;  Angiotensin peptides;  Intracrine
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.005
摘要:
随着肾素-血管紧张素系统肽谱的逐渐丰富，传统的肾素-血管紧张素系统正在经历重大的修正。研究发现目前正在广泛使用的血管紧张素系统抑制剂对心脏疾病的有益作用低于预期，这导致新的由非肾素途径介导的、具有高度特异性和组织/细胞依赖性的血管紧张素Ⅱ形成机制的提出。现综述血管紧张素-(1-12)是细胞内血管紧张素Ⅱ的主要替代底物，独立于循环肾素-血管紧张素系统，以及糜蛋白酶作为转化酶在其中的关键作用。
Abstract:
With the gradual enrichment of the peptide spectrum of renin-angiotensin system, the traditional renin-angiotensin system is undergoing major corrections.The study found that the currently widely used angiotensin system inhibitors have less beneficial effects in the heart diseases than expected,and this leads to the new proposal of mechanism of angiotensin II formation mediated by non-renin pathways,with high specificity and histo/cell dependence.This review addresses that angiotensin-(1-12) ,as a major endogenous substrate of intracellular angiotensinⅡ,is independent of the circulating renin-angiotensin system,and chymase is as a key enzyme in the heart

参考文献/References:

[1] Ahmad S,Varagic J,Groban L,et al. Angiotensin-(1-12):a chymase-mediated cellular angiotensinⅡ substrate[J] . Curr Hypertens Rep,2014,16(5):429.

[2] 谭漪扬,周建中. 慢性心力衰竭治疗新进展[J]. 心血管病学进展,2016,37(1):42-45.

[3] Hussain M,Awan FR. Hypertension regulating angiotensin peptides in the pathobiology of cardiovascular disease[J]. Clin Exp Hypertens,2018,40(4):344-352.

[4] Ferrario CM,Ahmad S,Varagic J,et al. Intracrine angiotensinⅡ functions originate from noncanonical pathways in the human heart[J] . Am J Physiol Heart Circ Physiol,2016,311(2):H404-H414.

[5] Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensinⅡ-receptor blockers for ischemic heart disease[J]. Ann Intern Med,2009,151(12):861-871.

[6] van Vark LC,Bertrand M,Akkerhuis KM,et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension:a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients[J]. Eur Heart J,2012,33(16):2088-2097.

[7] Brugts JJ,van Vark L,Akkerhuis M,et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension:a number-needed-to-treat analysis[J] . Int J Cardiol,2015,181:425-429.

[8] Ola MS,Alhomida AS,Ferrario CM,et al. Role of tissue renin-angiotensin system and the chymase/angiotensin-(1-12) axis in the pathogenesis of diabetic retinopathy[J]. Curr Med Chem,2017,24(28):3104-3114.

[9] Ahmad S,Wei CC,Tallaj J,et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts[J]. J Am Soc Hypertens,2013,7(2):128-136.

[10] Ahmad S,Simmons T,Varagic J,et al. Chymase-dependent generation of angiotensinⅡ from angiotensin-(1-12) in human atrial tissue[J] . PLoS One,2011,6(12):9.

[11] Nagata S,Varagic J,Kon ND,et al. Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue[J]. Ther Adv Cardiovasc Dis,2015,9(4):168-180.

[12] de Mello WC,Dell’Itallia LJ,Varagic J,et al. Intracellular angiotensin-(1-12) changes the electrical properties of intact cardiac muscle[J]. Mol Cell Biochem,2016,422(1-2):31-40.

[13] Bujak-Gizycka B,Olszanecki R,Suski M,et al. Angiotensinogen metabolism in rat aorta:robust formation of proangiotensin-12[J]. J Physiol Pharmacol,2010,61(6):679-682.

[14] Ferrario CM,Ahmad S,Nagata S,et al. An evolving story of angiotensin-Ⅱ-forming pathways in rodents and humans[J]. Clin Sci,2014,126(7-8):461-469.

[15] Nagata S,Hatakeyama K,Asami M,et al. Big angiotensin-25:a novel glycosylated angiotensin-related peptide isolated from human urine[J]. Biochem Biophys Res Commun,2013,441(4):757-762.

[16] Chitravanshi VC,Proddutur A,Sapru HN. Cardiovascular actions of angiotensin-(1-12) in the hypothalamic paraventricular nucleus of the rat are mediated via angiotensinⅡ[J]. Exp Physiol,2012,97(9):1001-1017.

[17] Chitravanshi VC,Sapru HN. Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat[J]. Am J Physiol Heart Circ Physiol,2011,300(1):H230-H240.

[18] Arakawa H,Chitravanshi VC,Sapru HN. The hypothalamic arcuate nucleus:a new site of cardiovascular action of angiotensin-(1-12) and angiotensinⅡ[J]. Am J Physiol Heart Circ Physiol,2011,300(3):H951-H960.

[19] Arakawa H,Kawabe K,Sapru HN. Angiotensin-(1-12) in the rostral ventrolateral medullary pressor area of the rat elicits sympathoexcitatory responses[J]. Exp Physiol,2013,98(1):94-108.

[20] Ferrario CM,VonCannon J,Jiao Y,et al. Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene[J]. Am J Physiol Heart Circ Physiol,2016,310(8):H995-1002.

[21] Varagic J,Ahmad S,VonCannon JL,et al. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats[J]. Am J Hypertens,2013,26(5):583-590.

[22] Ahmad S,Ferrario CM. Chymase inhibitors for the treatment of cardiac diseases:a patent review (2010-2018)[J]. Expert Opin Ther Pat,2018,28(11):755-764.

[23] Dell’Italia LJ,Collawn JF,Ferrario CM. Multifunctional role of chymase in acute and chronic tissue injury and remodeling[J]. Circ Res,2018,122(2):319-336.

[24] Nagata S,Varagic J,Simington SW,et al. Differential expression of angiotensin-(1-12)/chymase in human atrial tissue[J]. Hypertension,2013,62(3):1.

[25] Takai S,Jin D,Miyazaki M. Multiple mechanisms for the action of chymase inhibitors[J]. J Pharmacol Sci,2012,118(3):311-316.

[26] Ferrario CM,Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease[J]. Pharmacol Res,2017,125(Pt A):57-71.

[27] Wei CC,Hase N,Inoue Y,et al. Mast cell chymase limits the cardiac efficacy of AngⅠ-converting enzyme inhibitor therapy in rodents[J]. J Clin Invest,2010,120(4):1229-1239.

[28] Kanefendt F,Thuss U,Becka M,et al. Pharmacokinetics,safety,and tolerability of the novel chymase inhibitor BAY 1142524 in healthy male volunteers[J]. Clin Pharmacol Drug Dev,2019,8(4):467-479.

更新日期/Last Update: 2020-01-19